晚期非小细胞肺癌的二线治疗：临床实践的新证据 - Suppr

Suppr

超能文献

Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.

作者信息

Tassinari D, Drudi F, Lazzari-Agli L, Tombesi P, Sartori S

机构信息

Pneumo-Oncology Unit, Department of Oncology.

出版信息

Ann Oncol. 2010 Feb;21(2):428-429. doi: 10.1093/annonc/mdp538. Epub 2009 Nov 17.

DOI:10.1093/annonc/mdp538

PMID:19920059

Abstract

摘要

相似文献

Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.晚期非小细胞肺癌的二线治疗：临床实践的新证据

Ann Oncol. 2010 Feb;21(2):428-429. doi: 10.1093/annonc/mdp538. Epub 2009 Nov 17.

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.复发性或进展性非小细胞肺癌的二线或后续全身治疗：一项系统评价与实践指南

J Thorac Oncol. 2006 Nov;1(9):1042-58.

Salvage therapy in patients with advanced non-small cell lung cancer.晚期非小细胞肺癌患者的挽救治疗。

J Thorac Oncol. 2006 Jul;1(6):582-7.

Taxane-platinum combinations in advanced non-small cell lung cancer: a review.晚期非小细胞肺癌中紫杉烷与铂类的联合应用：综述

Oncologist. 2004;9 Suppl 2:16-23. doi: 10.1634/theoncologist.9-suppl_2-16.

Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.多西他赛每周给药作为晚期非小细胞肺癌的二线化疗：随机试验的荟萃分析

Cancer Treat Rev. 2006 Dec;32(8):583-7. doi: 10.1016/j.ctrv.2006.07.003. Epub 2006 Aug 21.

Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).晚期非小细胞肺癌（NSCLC）治疗中的二线化疗

J Chemother. 2004 Nov;16 Suppl 4:104-7. doi: 10.1179/joc.2004.16.Supplement-1.104.

Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.卡铂联合每两周一次多西他赛治疗晚期非小细胞肺癌的II期研究

J Thorac Oncol. 2006 Nov;1(9):979-83.

Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.每周使用长春瑞滨和多西他赛作为预处理非小细胞肺癌患者的二线化疗：一项I-II期试验。

J Chemother. 2004 Aug;16(4):392-9. doi: 10.1179/joc.2004.16.4.392.

Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.多西他赛与卡铂用于老年晚期非小细胞肺癌患者的II期研究。

J Thorac Oncol. 2009 Mar;4(3):371-5. doi: 10.1097/JTO.0b013e31819846e4.

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.多西他赛每3周一次与每周一次用于预处理的晚期非小细胞肺癌的随机III期研究：一项西班牙肺癌研究组试验

Ann Oncol. 2006 Mar;17(3):467-72. doi: 10.1093/annonc/mdj115. Epub 2005 Dec 21.

引用本文的文献

Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment.盐酸安罗替尼联合PD-1阻断作为标准治疗半年后局部晚期非小细胞肺癌进展患者的挽救性二线治疗方案

Onco Targets Ther. 2022 Oct 17;15:1221-1228. doi: 10.2147/OTT.S380615. eCollection 2022.

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).安罗替尼三线治疗晚期难治性非小细胞肺癌的多中心、随机、II 期临床研究（ALTER0302）。

Br J Cancer. 2018 Mar 6;118(5):654-661. doi: 10.1038/bjc.2017.478. Epub 2018 Feb 13.

Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life.在常规临床实践中用培美曲塞治疗 III/IV 期非小细胞肺癌（NSCLC）的二线治疗：对体能状态和健康相关生活质量的评估。

BMC Cancer. 2012 Jan 13;12:14. doi: 10.1186/1471-2407-12-14.

[Implications of modern anticancer therapies for palliative care concepts].[现代抗癌疗法对姑息治疗理念的影响]

Schmerz. 2010 Dec;24(6):633-41. doi: 10.1007/s00482-010-0940-0.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验